Galecto, INC Schedule 13G passive stakes

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has disclosed a 2.0% passive beneficial ownership stake in Damora Therapeutics, Inc.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 6.27% of Damora Therapeutics, Inc. common stock as of March 31, 2026.

Paramora Holding LLC has reduced its position in Damora Therapeutics to 3.39%, falling below the 5% regulatory reporting threshold.

Paragon Therapeutics, Inc. disclosed a 3.39% beneficial ownership stake in Damora Therapeutics, Inc. via a Schedule 13G filing.

Ikarian Capital, LLC and Neil Shahrestani have filed an amended Schedule 13G, reporting a 0.6% beneficial ownership stake in Galecto, Inc.

Paramora Holding LLC has reported a 7.5% beneficial ownership stake in Galecto, Inc.'s common stock, excluding convertible preferred shares.

Paragon Therapeutics, Inc. has reported a 7.5% beneficial ownership stake in Galecto, Inc.'s common stock, excluding shares from convertible preferred stock pending stockholder approval.

Ikarian Capital, LLC and Neil Shahrestani have reported a 21.5% beneficial ownership stake in Galecto, Inc., holding 285,710 shares of common stock.

FMR LLC and Abigail P. Johnson have reported a 15.0% beneficial ownership stake in Galecto, Inc., totaling 238,878 shares of common stock.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a 6.3% beneficial ownership stake in Galecto, Inc.